Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Chemours, Lowers Price Target to $33

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $41 to $33.
byBenzinga Newsdesk
October 25, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $41 to $33.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0